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The enabling technology for dose mapping, treatment evaluation and 
adaptation based upon cumulative dose is deformable image 
registration (DIR).  Ideally, DIR creates an exact correspondence 
between tissue sub-volumes in the co-registered images.  
Realistically, DIR creates an approximate map of image content (e.g. 
grey-scales, landmarks, contours) between two images.  As a result, 
current DIR algorithms yield an imperfect correspondence between 
tissue elements for both intra- and inter-fraction registration.  Since 
tissue response is a function of the accumulated and per fraction dose 
to each sub-volume, registration errors add uncertainty to patient 
dose evaluation.  Unfortunately, necessary and sufficient methods do 
not exist for automated patient DIR validation; however, several 
necessary but insufficient methods do exist.  This presentation will (1) 
describe the use of inverse mapping consistency and unbalanced 
energy to detect DIR errors; (2) probe the correspondence of these 
metrics with dose mapping errors and cumulative dose uncertainty; 
(2) explain a 3D distance-to-difference (DTD) metric which can be 
used to determine DIR error tolerances sufficient to keep dose 
mapping errors below a user-specified threshold; (3) demonstrate the 
necessity for self-consistent registrations in adaptive treatment 
protocols paradigms in which accumulated dose is projected on to the 
anatomy of the day; (4) illustrate methods to evaluate random 
registration uncertainties and the corresponding dose uncertainties; 
and (5) look at the impact of correlated registration errors on patient 
dose distributions.  Even though DIR and dose mapping is imperfect, it 
can be clinically beneficial if it improves the estimate of the 
accumulated patient dose.  Users must be keenly aware of potential 
errors and their consequences. 
   
 LOOK INSIDE: TREATMENT REPRODUCIBILITY: WHERE 
IMAGING CANNOT REPRESENT THE REALITY  
  
SP-0520  
3D vs 4D CBCT: Clinical indications, implementation, and 
practicalities 
C. Brink1 
1Odense University Hospital, Laboratory of Radiation Physics, Odense, 
Denmark  
 
3D imaging represents a snapshot in time of the patient anatomy. By 
use of 4D imaging, either as imaging of the respiration cycle or as 
consecutive 3D images over thetreatment course, dynamics of the 
anatomy can be measured and included in the treatment planning 
process. However, due to the added information/complexity by use of 
4D techniques relative to 3D imaging there can be some hesitations 
implementing 4D imaging clinically. 
The intent of using 4D imaging can be numerous. Currently, the main 
purpose of CBCT imaging is to ensure the correct treatment position 
of the patient. Use of 4D CBCT can ensure that the tumour is imaged 
with less image artefacts and with the tumour in an average position. 
This can reduce the treated volume significantly.   
However, 4D imaging can also be used to e.g. monitor changes of the 
volume of a lung tumour over the treatment course. Studies 
correlating tumour volume changes to clinical outcome are starting to 
appear. Based on such a correlation it might be possible to adapt the 
treatment to the specific patient e.g. as an accelerated treatment. 
Similarly there are also studies which investigate the possibility to use 
CBCT as a way to predict expected toxicity. 
CBCT imaging can also potentially be used for recalculation of the 
treatment dose. For standard CBCT a unique link between electron 
density and CBCT value does not exist. This prevents calculation of 
dose which includes correction for density variations within the 
patient. The cause of the problem is scattered dose reaching the 
detector. The expected scatter contribution can be corrected by use 
of Monte Carlo techniques which is feasible today on small computer 
clusters within clinically relevant times. 
The above use of 4D imaging requires different degree of image 
quality. Since image quality is related to imaging dose and time the 
specific goal of the imaging needs to be defined in order to get the 
maximum benefit of 4D CBCT. Having considered the imaging goal a 
number of practical issues related to the use of 4D CBCT appear e.g. 
which respiration phase should be used in validating patient position, 
which respiration phase should be used for treatment calculation, 
what if mediastinal nodes and lung tumour do not move 
synchronously, how to optimise workflow and minimise imaging dose, 
and what education is needed to evaluate the additional information. 
Conclusion: 4D CBCT has been available for a number of years and has 
the potential not only to optimise the treatment position of the 
patient, but also to measure patient specific response to the delivered 
treatment. In implementation of 4D imaging it is obviously important 
to realise the main goal of the imaging, but also to realise that the 
additional acquired information adds a number of practical issues and 
that additional education of treatment staff is necessary in order to 
maximise the benefit of the imaging. 
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Respiratory management can provide a potential for increasing 
positional precision, which can facilitate dose escalation with 
maintained healthy tissue toxicity.Respiratory management can 
include breath-holding, beam gating or tumour tracking during 
irradiation. However, performing such manoeuvres in a safe manner is 
not trivial, although the technical capabilities are to a large extent 
available. It has been shown that huge variations in respiratory 
pattern can be present both intra- and inter-fraction, and that 
correlation between respiratory surrogates and actual tumour motion 
may not be consistent from session to session. Target localisation 
through respiratory monitoring and correlation must therefore be 
performed in a consistent manner during treatment preparation, and 
for each instance of treatment delivery.  
There are basically two challenges related to target localisation 
adequate for respiratory management; achieving target visibility and 
achieving representative positional information. Both of these 
challenges are most easily met by using more complex imaging 
methods over longer duration of time.However, there may on the 
other hand be motivation for limiting the amount and complexity of 
imaging, related to availability, work-flow, risk management and cost-
effectiveness.  
This presentation goes through some specific examples exhibiting 
target localisation challenges, and solutions for balancing complexity 
and amount of imaging with these other factors. 
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In radiation therapy, intra-fraction motion results in significant 
geometric and dosimetric uncertainties in the therapeutic dose 
delivery treating thoracic and abdominal tumors. Technological 
evolution has brought new possibilities into the field which enable 
active dynamic compensation of intra-fraction movements of the 
tumor, limiting the volume of surrounding tissue exposed to high 
doses. Real-time tumor tracking (RTTT) is a fairly recent motion 
compensation technique, which involves a complex workflow. The 
currently available linac systems supporting this technique all use a 
so-called hybrid approach to locate the moving tumor during tracking. 
In a preparatory step, repeated X-ray images are acquired together 
with a synchronized acquisition of the breathing signal from the 
patient skin movement. A dedicated mathematical model is optimized 
to fit the correlation between external breathing signal and internal 
tumor motion. The motion compensation is driven by the external 
signal and the model. This allows reduction of additional imaging dose 
and can be used to introduce some robustness to irregular breathing. 
However it does also introduce some residual tracking error due to 
suboptimal fit and the correlation model prediction accuracy has a 
limited validity in time due to possible systematic drifts in the 
breathing pattern and movement of the patient. As such the 
performance of these RTTT solutions is dependent on the correlation 
model but also on the time efficiency, to minimize possible drifting. 
The pre-treatment imaging, the treatment planning process and PTV 
volume definition should incorporate the dynamic nature of the RTTT 
process with 4D CT imaging and dose accumulation. In terms of quality 
assurance (QA), also for tumor tracking, the amount  of patient 
specific QA and the machine related QA should be balanced. Moving 
phantom experiments can be performed in combination with various 
dosimetry techniques. However, RTTT is a type of radiotherapy 
treatment adaptation which involves a continuous interaction 
between a technical system and the patient. As such, part of the 
commissioning of such a system and also routine patient specific QA 
